Investigation of the Effect of Preoperative Hypoalbuminemia, Blood Urea Nitrogen and Creatinine Levels on Postoperative Atrial Fibrillation on Off-Pump Coronary Bypass Surgery Patients
Hypoalbuminemia is a Risk Factor for Atrial Fibrillation
Keywords:hypoalbuminemia, atrial fibrillation, coronary artery bypass, off-pump bypass
Background: Postoperative atrial fibrillation (PoAF) is one of the most common complications to occur after open heart surgery. It has been shown that hypoalbuminemia accompanies some cardiovascular disorders. The present study evaluates the effects of pre-procedural albumin, blood urea nitrogen (BUN), and creatinine levels on PoAF.
Methods: The data of 81 patients who underwent off-pump coronary artery bypass graft (CABG) surgery was evaluated. Patients who developed atrial fibrillation (AF) in the first 48 hours post surgery constituted the PoAF (+) group, while those without AF constituted the PoAF (-) group. The pre-procedural hematological parameters of patients in both groups were included in the analysis.
Results: The PoAF (+) group was comprised of 57 patients (70.3%) with a mean age of 65.5 ± 9.8 years, while the PoAF (-) group was comprised of 24 patients (29.7%) with a mean age of 60.6 ± 9.6 years. A comparison of the demographic characteristics of the two groups showed that age (P = .036), frequency of renal failure (P = .007), and frequency of DM
(P = .001) were higher in the PoAF (+) group. An examination of the laboratory data revealed a negative correlation between Hct (P = .001) and albumin (P = .000) levels and presence of PoAF. Also, the MPV (P = .02), BUN (P = .007), and Cr
(P = .043) values were higher in the PoAF (+) group.
Conclusion: The present study, whose focus was on the effects of albumin levels on the occurrence of PoAF, found that low levels of pre-procedural albumin, as one of the major proteins in the blood, is a risk factor for the development of PoAF.
Allison SJ. 2013. Chronic kidney disease: ESRD risk in CKD patients with incident atrial fibrillation Nat Rev Nephrol 9:125.
Arques S, Ambrosi P. 2011. Human serum albumin in the clinical syndrome of heart failure. J Card Fail. 17:451–458.
Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. 2013. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease Circulation. Feb 5;127(5):569-74.
Baranyi A, Rothenhäusler H-B. 2012. The impact of intra- and postoperative albumin levels as a biomarker of delirium after cardiopulmonary bypass: results of an exploratory study. Psychiatry Res. 200(2-3):957-963.
Camm J, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. 2010. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur. Heart J., 31 pp. 2369-2429.
Chien SC, Chen CY, Lin CF, Yeh HI. 2017. Critical appraisal of the role of serum albumin in cardiovascular disease Biomark Res. Nov 10;5:31.
Dongaonkar RM, Stewart RH, Geissler HJ, et al. 2010. Myocardial microvascular permeability, interstitial oedema, and compromised cardiac function. Cardiovasc Res. 87:331–339.
Elwell RJ, Spencer AP, Eisele G. 2003. Combined furosemide and human albumin treatment for diuretic-resistant edema. Ann Pharmacother. 37:695–700.
Engin M, Aydın C. 2020. Investigation of the Effect of HATCH Score and Coronary Artery Disease Complexity on Atrial Fibrillation After On-Pump Coronary Artery Bypass Graft Surgery Med Princ Pract. May 18.
Erdolu B, As AK, Engin M. 2020. The Relationship between the HATCH Score, Neutrophil to Lymphocyte Ratio and Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Graft Surgery. The Heart Surgery Forum 23(1); 88-92.
Fagyas M, Úri K, Siket IM, et al. 2014. New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human. Karamyan V, ed. PLoS One. 9(4):e87844.
Feng C, Mei W, Luo C, et al. 2013. Relationship between mean platelet volume and coronary blood flow in patients with atrial fibrillation. Heart Lung Circ. 22:43-9.
Francis GL. 2010. Albumin and mammalian cell culture: implications for biotechnology applications. Cytotechnology 62:1–16.
Goudis CA, Korantzopoulos P, Ntalas IV, Kallergis EM, Liu T, Ketikoglou DG. 2015. Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies Int J Cardiol. Apr 1;184:617-22.
Greenberg JW, Lancaster TS, Schuessler RB, Melby SJ. 2017. Postoperative atrial fibrillation following cardiac surgery: a persistent complication Eur J Cardiothorac Surg. Oct 1;52(4):665-672.
Guajardo Salinas GE, Nutt R, Rodriguez-Araujo G. 2017. Del Nido cardioplegia in low risk adults undergoing first time coronary artery bypass surgery. Perfusion. 32(1):68-73.
Guenancia C, Pujos C, Debomy F, Malapert G, Laurent G, Bouchot O. 2015. Incidence and Predictors of New-Onset Silent Atrial Fibrillation after Coronary Artery Bypass Graft Surgery. Biomed Res Int 2015:703685.
Júnior MSB, Matkovski PD, Di Giovanni FJ, Fenili R, Varella EL, Dietrich A. 2015. Incidence of postoperative atrial fibrillation in patients undergoing on-pump and off-pump coronary artery bypass grafting. Braz J Cardiovasc Surg 30:316-24.
Kodani E, Atarashi H, Inoue H, et al. 2018. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. Eur Heart J Qual Care Clin Outcomes. 4(1):59-68.
Kowalewski M, Jasiński M, Staromłyński J, et al. 2020. On-Pump vs Off-Pump coronary artery bypass surgery in atrial fibrillation. Analysis from the polish national registry of cardiac surgery procedures (KROK) PLoS One 15(4):e0231950.
Kozlovski VI, Lomnicka M, Jakubowski A, Chlopicki S. 2007. Inhibition of neutral endopeptidase by thiorphan does not modify coronary vascular responses to angiotensin I, angiotensin II and bradykinin in the isolated guinea pig heart. Pharmacol Rep. 59(4):421-427.
Mapanga RF, Joseph DE, Saieva M, et al. 2017. Glycation abolishes the cardioprotective effects of albumin during ex vivo ischemia-reperfusion. Physiol Rep. 5(2):e13107.
Movahed R, Hashemzadeh M, Jamal MM. 2005. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease, Int. J. Cardiol. 105 315–318.
Novack V, Pencina M, Zahger D, et al. 2010. Routine laboratory results and thirty day and one-year mortality risk following hospitalization with acute decompensated heart failure. PLoS One. 5:e12184.
Okutucu S, Öztürk D, Oto E, Güvenir HA, Karaagaoglu E. 2017. Data mining experiments on the angiotensin II- Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF - AFNET 2) trial: 'exposing the invisible' Europace. May 1;19(5):741-746.
Ozsin KK, Sanri US, Toktas F, Yavuz S. 2018. Relationship between red cell distribution width and mean platelet volume with new onset atrial fibrillation after off-pump coronary artery bypass grafting Bratisl Lek Listy. 119(6):335-34.
Öztürk İ, Öztürk S. 2015. Association between postoperative atrial fibrillation and the levels of hemoglobin or hematocrit: a systematic review and metaanalysis Anaesthesia, Pain & Intensive Care Jul 19; 3: 247-253.
Phan K, Ha HS, Phan S, Medi C, Thomas SP, Yan TD. 2015. New-onset atrial fibrillation following coronary bypass surgery predicts long-term mortality: a systematic review and meta-analysis Eur J Cardiothorac Surg. Dec;48(6):817-24.
Providência R, Faustino A, Paiva L, et al. 2013. Mean platelet volume is associated with the presence of left atrial stasis in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 10;13:40.
Roche M, Rondeau P, Singh NR, et al. 2008. The antioxidant properties of serum albumin. FEBS Lett. 582:1783–1787.
Sanchez de Léon R, Paterson JL, Sykes MK. 1982. Changes in colloid osmotic pressure with plasma albumin concentration associated with extracorporeal circulation. BrJAnaesth. 54(4):465-473.
Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. 1990. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest. 86(6):1913-1920.
Shen J, Lall S, Zheng V, Buckley P, Damiano RJ, Jr Schuessler RB. 2011. The persistent problem of new-onset postoperative atrial fibrillation: a single-institution experience over two decades J Thorac Cardiovasc Surg 141:559–70.
Soeters PB, Wolfe RR, Shenkin A. 2019. Hypoalbuminemia: Pathogenesis and Clinical Significance. JPEN J Parenter Enteral Nutr. 43(2):181-193.
van Beek DEC, van der Horst ICC, de Geus AF, Mariani MA, Scheeren TWL. 2018. Albumin, a marker for post-operative myocardial damage in cardiac surgery J Crit Care. Oct;47:55-60.
Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S. 2011. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 22:349–357.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).